CAR T Cell Therapy for Brain Tumors

(IMPACT MET Trial)

This trial aims to test the safety of a new CAR T cell therapy for adults with brain tumors that have spread from another cancer. Researchers seek to determine the treatment's effectiveness for individuals with new or recurring tumors after previous treatments. It is best suited for those whose cancer has returned or progressed and who have confirmed CD70 (a specific protein) on their cancer cells. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial requires that you stop any investigational therapy before joining. If you're on chemotherapy or immunotherapy, you must stop at least 14 days before starting the trial. The protocol doesn't specify about other medications, so it's best to discuss with the trial team.

Earlier studies have tested a new treatment called IL-8 receptor-modified CD70 CAR T cell therapy to assess its safety and practicality. These studies focus on using this treatment for brain tumors in adults. So far, the treatment appears safe for patients. Researchers are exploring this therapy because it targets CD70, a protein found on some tumor cells.

Most treatments for brain tumors, like surgery, radiation, and chemotherapy, aim to remove or kill tumor cells directly but can harm healthy cells too. Unlike these standard options, the IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy is unique because it uses the body’s own immune cells, specifically engineered to target and attack tumor cells with precision. This therapy modifies T cells to recognize a protein called CD70 on tumor cells, potentially improving their ability to distinguish cancerous cells from normal ones. Researchers are excited because this approach could lead to more targeted, effective treatments with fewer side effects, opening up new possibilities for patients with brain tumors.

Research has shown that IL-8 receptor-modified CD70 CAR T cell therapy may help treat brain tumors, particularly those with the CD70 marker. In one study, these modified cells effectively targeted glioblastoma, a type of brain cancer. This therapy enhances the immune system's ability to locate and destroy cancer cells. Early research also suggests it could be promising for patients whose cancer has metastasized to the brain. Although more studies are needed, these findings offer hope for improved treatment outcomes. Participants in this trial will receive one of two dose levels of this therapy to evaluate its effectiveness and safety.¹⁶⁷⁸⁹